Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Peptide to Antagonize GRPR for Oncology?
Peptide to Antagonize GRPR for Oncology is a peptide commercialized by Novartis, with a leading Phase II program in Metastatic...
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Peptide to Antagonize GRPR for Oncology?
Peptide to Antagonize GRPR for Oncology is a peptide commercialized by Novartis, with a leading Phase II program in Metastatic...